ReviewCalcified tissue international2011
Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis.
Review in Calcified tissue international, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
92 citing papers in PubMed, 5 syntheses or guidelines pooled it, 204 citations in OpenAlex.
- Systematic review of the prevalence and nature of drug-related problems in paediatric patients.Journal of clinical pharmacy and therapeutics · 2022Pooled it
- European guidance for the diagnosis and management of osteoporosis in postmenopausal women.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2019Guideline
- Recommendations for preventing fracture in long-term care.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2015Guideline
- Bisphosphonates in the management of thalassemia-associated osteoporosis: a systematic review of randomised controlled trials.Journal of bone and mineral metabolism · 2014Pooled it
- European guidance for the diagnosis and management of osteoporosis in postmenopausal women.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2013Guideline
- Acute Effects of Kisspeptin Administration on Bone Metabolism in Healthy Men.The Journal of clinical endocrinology and metabolism · 2022Trial
- Effectiveness of monthly intravenous ibandronate on the low responders to oral bisphosphonate: the MOVEMENT study.Journal of bone and mineral metabolism · 2019Trial
- Hypocalcaemia after denosumab in older people following fracture.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2017Trial
- Patient preference for monthly bisphosphonate versus weekly bisphosphonate in a cluster-randomized, open-label, crossover trial: Minodroate Alendronate/Risedronate Trial in Osteoporosis (MARTO).Journal of bone and mineral metabolism · 2016Trial
- Bakuchiol Ameliorates Glucocorticoid-Induced Osteoporosis by Enhancing Osteoblast Differentiation via Targeting FAT4 to Activate YAP1.Phytotherapy research : PTR · 2026Article
- [Evidence-based management of acute-phase reaction following zoledronic acid].Zeitschrift fur Rheumatologie · 2026Article
- Real-world pharmacovigilance of drug-induced osteoporosis: a focus on antiretroviral therapy and toxicological mechanisms in the elderly.Frontiers in pharmacology · 2026Article
- Article
- Trajectory-Ordered Objectives for Self-Supervised Representation Learning of Temporal Healthcare Data Using Transformers: Model Development and Evaluation Study.JMIR medical informatics · 2025Article
- A comprehensive review and advanced biomolecule-based therapies for osteoporosis.Journal of advanced research · 2025Review
- Advancing care: optimizing osteoporosis treatment in the older and oldest old population.Aging clinical and experimental research · 2025Review
- Chiral Supramolecular Hydrogels Regulating Both Osteoblastogenesis and Osteoclastogenesis.Gels (Basel, Switzerland) · 2025Article
- Strategic incorporation of metal ions in bone regenerative scaffolds: multifunctional platforms for advancing osteogenesis.Regenerative biomaterials · 2025Review
- Efficacy and safety of bisphosphonates in pediatric glucocorticoid-induced osteoporosis: a meta-analysis and pharmacovigilance study.Frontiers in pediatrics · 2025Article
- The calcium-sensing receptor: a comprehensive review on its role in calcium homeostasis and therapeutic implications.American journal of translational research · 2025Review
32 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 9 institutions in 6 countries.
Funding
Abstract
The pharmacological management of disease should involve consideration of the balance between the beneficial effects of treatment on outcome and the probability of adverse effects. The aim of this review is to explore the risk of adverse drug reactions and drug-drug interactions with treatments for postmenopausal osteoporosis. We reviewed evidence for adverse reactions from regulatory documents, randomized controlled trials, pharmacovigilance surveys, and case series. Bisphosphonates are associated with gastrointestinal effects, musculoskeletal pain, and acute-phase reactions, as well as, very rarely, atrial fibrillation, atypical fracture, delayed fracture healing, osteonecrosis of the jaw, hypersensitivity reactions, and renal impairment. Cutaneous effects and osteonecrosis of the jaw are of concern for denosumab (both very rare), though there are no pharmacovigilance data for this agent yet. The selective estrogen receptor modulators are associated with hot flushes, leg cramps, and, very rarely, venous thromboembolism and stroke. Strontium ranelate has been linked to hypersensitivity reactions and venous thromboembolism (both very rare) and teriparatide with headache, nausea, dizziness, and limb pain. The solidity of the evidence base depends on the frequency of the reaction, and causality is not always easy to establish for the very rare adverse reactions. Drug-drug interactions are rare. Osteoporosis treatments are generally safe and well tolerated, though they are associated with a few very rare serious adverse reactions. While these are a cause for concern, the risk should be weighed against the benefits of treatment itself, i.e., the prevention of osteoporotic fracture.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.